Intarcia Therapeutics Gets $210M For Diabetes Treatments

Hayward-based Intarcia Therapeutics announced Thursday that it has raised $210M in a combination of equity and debt. The developer of diabetes treatment said it raised $160M in a preferred stock private placement, and $50M in private debt. Investors in the funding included New Enterprise Associates, New Leaf Venture Partners Venrock, The Baupost Group, Farallon Capital Management, and three additional un-named institutional investors. Intarcia is developing treatment for type 2 diabetes, and is about to launch a Phase 3 program. More information »